Julian C. van Capelleveen

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Nicholas J. Viney, Julian C. van Capelleveen, Richard S. Geary et al. · The Lancet · 2016 · 748 citations

Medicine, Pharmacology, Clinical Pharmacology +6

Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease

Tom R. Webb, Jeanette Erdmann, Kathleen Stirrups et al. · Journal of the American College of Cardiology · 2017 · 266 citations · Full text

Life Sciences, Cardiology, Genetics +17

Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk

Julian C. van Capelleveen, Sophie J. Bernelot Moens, Xiaohong Yang et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2017 · 71 citations · Full text

Medicine, Cardiology, Epidemiology +16

ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels

Laia Trigueros‐Motos, Julian C. van Capelleveen, Federico Torta et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2017 · 66 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16

Arterial and Cellular Inflammation in Patients with CKD

Sophie J. Bernelot Moens, Simone L. Verweij, Fleur M. van der Valk et al. · Journal of the American Society of Nephrology · 2016 · 64 citations · Full text

Veterinary Medicine, Cardiology, Immunology +17